Insulet Stock: why GLP-1 fears are overblown, with growth driven by Europe/MENA expansion. Read here for a detailed analysis on PODD stock.

Insulet PODD appears well-poised on solid prospects in the diabetes market. The company continues to gain from strong Omnipod 5 and Omnipod DASH uptake globally. The stock carries a Zacks Rank #1 ...

Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.

Insulet Corporation's Omnipod 5 System received FDA clearance for type 2 diabetes in August. Insulet reported a 26% year-over-year revenue increase in Q2 2024, driven by strong demand for Omnipod 5.

Insulet stock (NASDAQ: PODD) currently trades around $200 per share, about 35% lower than the levels of over $300 seen in early November 2021. In comparison, its peer – DexCom stock – is down 55% over ...

Insulet’s modeled fair value has been trimmed from US$369.64 to US$354.40, signaling a more measured view of upside in the current setup. That shift lines up with Street research that is resetting ...

Insulet Corporation (NASDAQ:PODD) shares are trading higher after the company reported preliminary second-quarter results. The company reported preliminary revenue of $488 million for the second ...

Insulet stock is up on fourth-quarter results ahead of consensus, with company leaders talking about talent, technology, and ...

ClearBridge Investments, an investment management company, released its “ClearBridge Select Strategy” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S. equities ...

Insulet Corp. PODD announced that its Omnipod 5 Automated Insulin Delivery (“AID”) System is now compatible with Abbott’s ABT FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) sensor in the ...